Bristol-Myers Squibb reports second-quarter results on July 30 with the stock riding its strongest stretch in months, but the debate heading into the print centres on whether a rebuilt pipeline can replace the revenue Revlimid's genericization has been quietly draining.
The stock has climbed 12% over the past month to $62.09, putting it near its 52-week high and within a dollar of the consensus mean price target of $62.96. That tight gap between price and target matters: it means analysts have little room left to justify the recent re-rating without a strong forward outlook from management. Options positioning is relaxed rather than charged. The put/call ratio is running at 0.86, fractionally below its 20-day average of 0.88, and the z-score of -0.51 shows no unusual demand for downside protection. Borrow conditions are similarly unthreatening — availability runs at over 5,500% of shares outstanding, meaning the lending pool is essentially open. Short interest, at roughly 1.9% of the free float, is not a primary driver here, though it has ticked up about 11% over the past week after falling sharply through late June and early July.
The bull and bear cases map cleanly onto two questions: pipeline execution and revenue sustainability. Bulls point to milvexian in stroke prevention, admilparant in IPF, and Cobenfy's expansion into Alzheimer's disease psychosis as catalysts that could meaningfully replenish the portfolio — with Eliquis continuing to anchor near-term revenue. The stock has also re-emerged as a quality compounder on momentum metrics, with its 182-day relative strength now among the highest readings in six months and an F-score of 8 that competes well against peers including and . Bears focus on US market concentration and the pace of pipeline conversion — particularly the risk that mid- to late-stage programmes disappoint, which would leave BMY structurally dependent on maturing assets. BofA Securities, the most recent bellwether to act on July 10, kept its Buy rating but trimmed its target from $67 to $66, a signal of confidence tempered by near-term caution. Cantor Fitzgerald has held firm at Neutral with a $54 target, well below the current price — a meaningful dissent from the broader constructive tone.
Institutional ownership provides stability rather than signal. BlackRock added about 5.9 million shares in the most recent quarter to hold 8.4% of shares outstanding, and JPMorgan Asset Management added nearly 12.9 million shares to reach 3.8%. The pattern is consistent with passive and quasi-passive accumulation that follows the stock's re-entry into momentum screens — not an active vote on the July 30 outcome. Insider activity has been limited to small executive awards and tax-related sells, none of which materially alters the picture. In the two most recent comparable earnings events, BMY moved modestly on the day — roughly +1% and -1.4% respectively — but faded in the five sessions that followed, falling between 1.6% and 2.3% each time.
Thursday's print is ultimately a test of whether BMY's new-product ramp is tracking fast enough to justify a stock now priced at its consensus fair value, after a month that has already done much of the re-rating work.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
The short build in Bristol-Myers Squibb has continued at pace since Tuesday's note. Short interest now stands at 2.32% of free float — up another 20.8% in a single week and 60% over the past month. Bears that were…
Bristol-Myers Squibb enters the first week of June in an uncomfortable spot: the stock has shed 6.2% over the past week and 6.5% over the past month, while short sellers have been quietly rebuilding positions at the…
